doxazosin has been researched along with terazosin in 102 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 4 (3.92) | 18.7374 |
1990's | 24 (23.53) | 18.2507 |
2000's | 50 (49.02) | 29.6817 |
2010's | 22 (21.57) | 24.3611 |
2020's | 2 (1.96) | 2.80 |
Authors | Studies |
---|---|
Bondinell, WE; Hieble, JP; Ruffolo, RR | 1 |
Ballard, S; Blagg, J; Fox, D; Kenny, B | 1 |
Altenbach, RJ; Basha, FZ; Brune, ME; Buckner, SA; Carroll, WA; Condon, S; Drizin, I; Elmore, SW; Hancock, AA; Kerwin, JF; Meyer, MD; Sippy, KB; Tietje, K; Wendt, MD | 1 |
Topliss, JG; Yoshida, F | 1 |
Altenbach, RJ; Bai, H; Basha, FZ; Brune, ME; Buckner, SA; Carroll, WA; Drizin, I; Hancock, AA; Kerwin, JF; Lebold, SA; Lee, E; Meyer, MD; Pratt, JK; Sippy, KB; Tietje, K; Wendt, MD | 1 |
Pedretti, A; Testa, B; Villa, L; Vistoli, G | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Kinsella, GK; Rodriguez, F; Rozas, I; Watson, GW | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Sen, S; Sinha, N | 1 |
He, F; Huang, J; Huang, M; Huang, Y; Liu, X; Xiong, Y; Xu, X; Yang, Y; Yuan, M; Zhu, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Heinzl, S | 1 |
Kaplan, NM; Khoury, AF | 1 |
Anavekar, SN; Conway, EL; Drummer, OH; Howes, LG; Jarrott, B; Louis, WJ; McNeil, JJ; Workman, B | 1 |
Grimm, RH | 1 |
Hayduk, K | 1 |
Hayduk, K; Schneider, HT | 1 |
Stockamp, K | 1 |
Carter, AJ; Greengrass, PM; Kenny, BA; Naylor, AM; Read, AM; Wyllie, MG | 1 |
Kaplan, SA; Olsson, CA; Soldo, KA | 1 |
Chapple, CR | 2 |
Angeli-Greaves, M; Armas Padilla, MC; Armas-Hernández, MJ; Carvajal, AR; Guerrero Pajuelo, J; Hernández Hernández, R | 1 |
Ramage, AG; Wyllie, MG | 1 |
Beevers, DG; Marshall, HJ | 1 |
Frankel, S | 1 |
Brune, ME; Buckner, SA; Hancock, AA; Ireland, LM; Katwala, SP; Kerwin, JF; Milicic, I | 1 |
Vatz, KA | 1 |
Andersson, KE; Lepor, H; Wyllie, MG | 1 |
Fernández Arjona, M; Fernández Borrell, A; Gómez Sancha, F; Mínguez Martínez, R; Peinado Ibarra, F; Pereira Sanz, I | 1 |
Ikeguchi, E; Kaplan, SA; Santarosa, RP; Te, AE | 1 |
Beduschi, MC; Beduschi, R; Oesterling, JE | 1 |
Benos, DJ; Bradford, AL; Bubien, JK; Cornwell, T; DuVall, MD; Fuller, CM | 1 |
Chung, M; Hilbert, J; Lawrence, V; Phillips, K; Vashi, V | 1 |
Borkowski, A; Chon, JK; Isaacs, JT; Jacobs, SC; Kyprianou, N; Partin, AW | 1 |
Djavan, B; Marberger, M | 1 |
Hoffman, RM; Jansen, DJ; Resch, ND | 1 |
Clifford, GM; Farmer, RD | 1 |
Benning, CM; Kyprianou, N | 2 |
Benning, CM; Chon, J; Kyprianou, N | 1 |
Caprino, L | 1 |
Blanchard, K; Hananel, A; Rutchik, S; Sullivan, J | 1 |
Cotecchia, S; Goepel, M; Hein, P; Michel, MC | 1 |
Chao, J; Chrischilles, E; Gilden, D; Kreder, KJ; Rubenstein, L; Shah, H | 1 |
Akduman, B; Crawford, ED | 1 |
Jacobs, SC; Kyprianou, N | 1 |
Butler, WM; Galbreath, RW; Lief, JH; Merrick, GS; Wallner, KE | 1 |
Baykara, M; Ciftcioglu, MA; Emreoglu, I; Erdoğru, T; Gulkesen, KH; Koksal, T; Ozbilim, G; Usta, MF | 1 |
Alcaide, C; González-Juanatey, JR; Iglesias, MJ; Lago, F; Piñeiro, R | 1 |
Keledjian, K; Kyprianou, N | 1 |
Niu, CQ; Ren, LM | 1 |
Kyprianou, N | 1 |
Gonzalez, CM; McVary, KT | 1 |
Romics, I | 1 |
Bakshi, M; Ojha, T; Singh, S | 1 |
Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C | 1 |
Kyprianou, N; Tahmatzopoulos, A | 1 |
Brown, GA; Sussman, DO | 1 |
Ficker, EK; Hammerling, BC; Karle, CA; Katus, HA; Kiehn, J; Kuryshev, YA; Schoels, W; Thomas, D; Wimmer, AB; Wu, K | 1 |
Doggrell, SA | 1 |
Kyprianou, N; Rowland, RG; Tahmatzopoulos, A | 1 |
Dincel, C; Samli, MM | 1 |
Akbay, E; Bozlu, M; Cayan, S; Görür, S; Ulusoy, E | 1 |
Basar, H; Basar, MM; Batislam, E; Ferhat, M; Tuglu, D; Yilmaz, E | 1 |
Afshari, NA; Schwinn, DA | 1 |
Michel, MC; Noguchi, Y; Ohtake, A; Okutsu, H; Sasamata, M; Someya, A; Suzuki, M; Ukai, M; Watanabe, M; Yanai-Inamura, H; Yuyama, H | 1 |
de la Rosette, JJ; Michel, MC | 1 |
O'Leary, MP | 1 |
Akova, YA; Altan-Yaycioglu, R; Ozkardes, H; Tufan, H; Yaycioglu, O | 1 |
Baron, AT; Becker, A; Conner, W; Durbin, EB; Harris, AM; Kimbler, K; Kyprianou, N; Lane, M; Rowland, RG; Warner, BW; Wilson, JM | 1 |
Albo, G; Berardi, F; Colabufo, NA; Contino, M; de Rienzo, G; Niso, M; Pagliarulo, A; Pagliarulo, V; Perrone, R | 1 |
Jin, J; Kong, CZ; Li, NC; Na, YQ; Qiu, SP; Song, YS; Sun, G; Sun, YC; Sun, YH; Wang, XF; Wu, SL; Ye, ZQ | 1 |
Kitteringham, NR; Macdonald, I; Park, BK; Randle, LE; Sathish, JG; Williams, DP | 1 |
Mamalis, N | 1 |
Cheng, XR; Hua, CX; Hua, L; Huang, Y; Kang, J; Li, N; Li, YS; Liu, H; Ming, GH; Pang, HM; Wang, L; Wu, Y; Xu, L; Xu, ZM | 1 |
Bar-Yosef, Y; Kaver, I; Laufer, M; Mabjeesh, NJ; Matzkin, H; Neulander, EZ | 1 |
Hoyano, Y; Kobayashi, S; Kusama, H; Maruyama, K; Tomiyama, Y; Yamazaki, Y | 1 |
Kakumoto, M; Kobayashi, H; Ohnishi, N; Okumura, K; Sakaeda, T; Takara, K; Tanigawara, Y; Yokoyama, T | 1 |
Adomat, H; Elterman, DS; Fleshner, N; Guns, E; Hersey, K; Lawrentschuk, N; Wood, CA | 1 |
Chatziralli, IP; Sergentanis, TN | 1 |
Alan, C; Eren, AE; Ersay, AR; Ertung, Y; Kırılmaz, B; Koçoğlu, H | 1 |
Krome, S | 1 |
Du, H; He, L; Ren, J; Wang, S | 1 |
Casuccio, A; Cillino, G; Cillino, S; Pavone, C; Spitale, E | 1 |
Gandhi, HP; Giridhar, R; Naik, PP; Yadav, MR | 1 |
Hill, TM; McEwen, C; Sherman, JJ; Welch, RW | 1 |
Ahmed, S; El Zohny, SA; Mohamed, NA | 1 |
Araki, M; Araki, T; Monden, K | 1 |
Li, AP; Peng, H; Peng, JD; Zhang, J; Zhou, MQ | 1 |
Barkin, J; Berner, T; Diles, D; Franks, B | 1 |
Creta, M; Ficarra, V; Fusco, F; Giannarini, G; Longo, N; Mirone, V; Novara, G; Palmieri, A; Verze, P | 1 |
Anoopkumar-Dukie, S; Chess-Williams, R; Forbes, A; McDermott, C | 1 |
Anoopkumar-Dukie, S; Batty, M; Chess-Williams, R; Christie, D; Forbes, A; McDermott, CM; Pugh, R; Rathinam, I; Simmonds, J; Spencer, B; Walker, E | 1 |
Belayneh, M; Korownyk, C | 1 |
Derayea, SM; Hammad, MA; Mohamed, AA; Mohamed, AI; Omar, MA | 1 |
Hammad, MA; Omar, MA; Salman, BI | 1 |
Hori, Y; Ohyama, K; Sugiura, M | 1 |
Dahm, P; Hwang, EC; Koziarz, A; Kuntz, GM; Oestreich, MC; Sathianathen, NJ; Scales, CD; Vernooij, RW | 1 |
Liu, L; Narayanan, NS; Pottegård, A; Simmering, JE; Welsh, MJ | 1 |
32 review(s) available for doxazosin and terazosin
Article | Year |
---|---|
Alpha- and beta-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification.
Topics: Animals; Humans; Molecular Biology; Molecular Structure; Radioligand Assay; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta | 1995 |
Pharmacological options in the treatment of benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Controlled Clinical Trials as Topic; Endothelins; Enzyme Inhibitors; Humans; Male; Prostate; Prostatic Hyperplasia; Receptors, Adrenergic, alpha; Structure-Activity Relationship | 1997 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Prostatic adenoma: new drugs, new surgical techniques].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Androstenes; Azasteroids; Cystoscopes; Doxazosin; Finasteride; Humans; Male; Prazosin; Prostatectomy; Prostatic Hyperplasia; Stents | 1992 |
Alpha-blocker therapy of hypertension. An unfulfilled promise.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Hypertension; Lipids; Prazosin | 1991 |
Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Blood Pressure; Clonidine; Doxazosin; Humans; Hypertension; Prazosin | 1987 |
alpha 1-antagonists in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Doxazosin; Humans; Hypertension; Prazosin | 1989 |
[Therapy of benign prostatic hyperplasia with alpha receptor blockers].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Receptors, Adrenergic, alpha-1; Treatment Outcome; Urinary Bladder Neck Obstruction; Urodynamics | 1995 |
Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.
Topics: Adrenergic alpha-Antagonists; Blood Pressure; Clinical Trials as Topic; Doxazosin; Half-Life; Humans; Male; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Vasodilation | 1996 |
Measures of Proscar, Hytrin, and Cardura side effects.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia | 1997 |
Prostatic alpha 1-adrenoceptors and uroselectivity.
Topics: Adrenergic alpha-Antagonists; Animals; Doxazosin; Humans; Male; Prazosin; Prostate; Quinazolines; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 1997 |
[Alpha blockers in the treatment of benign hyperplasia of the prostate].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Humans; Indoramin; Male; Phenoxybenzamine; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 1997 |
Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Hormones; Humans; Male; Patient Selection; Plant Extracts; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 1998 |
Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin | 1998 |
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Controlled Clinical Trials as Topic; Dizziness; Dose-Response Relationship, Drug; Doxazosin; Humans; Hypotension, Orthostatic; Male; Middle Aged; Prazosin; Prognosis; Prostatic Hyperplasia; Quinazolines; Treatment Outcome; Urologic Diseases | 1999 |
Medical therapy for benign prostatic hyperplasia: a review of the literature.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Finasteride; Humans; Indoramin; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2000 |
[Drugs for the treatment of benign prostatic hypertrophy].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Aged; Androgen Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Middle Aged; Muscle, Smooth; Plant Extracts; Prazosin; Prostatic Hyperplasia; Receptors, Adrenergic, alpha-1; Serenoa; Sulfonamides; Tamsulosin; Urinary Bladder Neck Obstruction; Urodynamics | 2000 |
Terazosin, doxazosin, and prazosin: current clinical experience.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Doxazosin; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Randomized Controlled Trials as Topic; Receptors, Adrenergic, alpha | 2001 |
Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs.
Topics: Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Tumor Cells, Cultured | 2000 |
Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Topics: Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostate; Prostatic Hyperplasia; Structure-Activity Relationship; Treatment Outcome; Urinary Bladder Neck Obstruction | 2003 |
The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Disease Progression; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Treatment Outcome | 2003 |
[Pharmacologic treatment of benign prostatic hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2003 |
Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Doxazosin; Humans; Male; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Quinazolines | 2004 |
The role of alpha-blockers in the management of prostate cancer.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Angiogenesis Inhibitors; Anoikis; Doxazosin; Humans; Male; Prazosin; Prostatic Neoplasms; Quinazolines; Sulfonamides; Tamsulosin | 2004 |
Treatment and pharmacologic management of BPH in the context of common comorbidities.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Azasteroids; Cardiovascular Diseases; Comorbidity; Doxazosin; Drug Therapy, Combination; Dutasteride; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Global Health; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Transurethral Resection of Prostate; Treatment Outcome | 2006 |
[Alpha blockers in use for symptomatic benign prostatic hyperplasia--are all drugs born equal?].
Topics: Adrenergic alpha-Antagonists; Doxazosin; Evidence-Based Medicine; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin | 2008 |
Risk factors for intraoperative floppy iris syndrome: a meta-analysis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Diabetes Complications; Doxazosin; Humans; Hypertension; Incidence; Intraoperative Complications; Iris; Iris Diseases; Odds Ratio; Phacoemulsification; Prazosin; Quinazolines; Risk Factors; Sulfonamides; Syndrome; Tamsulosin | 2011 |
[How effective is finasteride?].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quality of Life; Sulfonamides; Tamsulosin | 2011 |
α1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies.
Topics: Adrenergic alpha-1 Receptor Antagonists; Clinical Trials as Topic; Doxazosin; Humans; Indoles; Male; Naphthalenes; Piperazines; Prazosin; Prostatism; Quinazolines; Severity of Illness Index; Sulfonamides; Tamsulosin; Urodynamics | 2016 |
The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Antineoplastic Agents; Doxazosin; Female; Humans; Male; Prazosin; Prostatic Neoplasms | 2016 |
Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.
Topics: Adrenergic alpha-Antagonists; Dizziness; Doxazosin; Humans; Hypotension; Lower Urinary Tract Symptoms; Male; Prazosin; Prostatic Hyperplasia; Randomized Controlled Trials as Topic | 2016 |
Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Chemotherapy, Adjuvant; Combined Modality Therapy; Doxazosin; Humans; Indoles; Kidney Calculi; Lithotripsy; Middle Aged; Prazosin; Quinazolines; Randomized Controlled Trials as Topic; Tamsulosin; Ureteral Calculi | 2020 |
13 trial(s) available for doxazosin and terazosin
Article | Year |
---|---|
alpha 1-antagonists in the treatment of hypertension.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Pressure; Doxazosin; Humans; Hypertension; Prazosin | 1989 |
Efficacy and safety of doxazosin in hypertension therapy.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Heart Rate; Humans; Hypertension; Lipids; Male; Middle Aged; Prazosin | 1987 |
Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Clinical Trials as Topic; Double-Blind Method; Doxazosin; Female; Humans; Hypertension; Male; Middle Aged; Prazosin | 1987 |
Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Pressure; Doxazosin; Drug Administration Schedule; Humans; Male; Middle Aged; Pilot Projects; Prazosin; Prostatic Hyperplasia; Urodynamics | 1995 |
Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Arteries; Blood Pressure; Cholesterol; Doxazosin; Female; Heart Rate; Humans; Hypertension; In Vitro Techniques; Lipids; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prazosin; Triglycerides | 1996 |
Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin.
Topics: Adrenergic alpha-Antagonists; Adult; Area Under Curve; Doxazosin; Drug Interactions; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Time Factors | 1998 |
Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Biopsy; Brachytherapy; Doxazosin; Follow-Up Studies; Humans; Iodine Radioisotopes; Male; Palladium; Postoperative Complications; Prazosin; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy, Conformal; Sulfonamides; Tamsulosin; Treatment Outcome; Urinary Retention; Urination Disorders | 2002 |
Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.
Topics: Clinical Trials as Topic; Doxazosin; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin | 2004 |
Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders.
Topics: Adrenergic alpha-Antagonists; Aged; Cross-Over Studies; Doxazosin; Humans; Male; Middle Aged; Prazosin; Prospective Studies; Prostatic Hyperplasia | 2004 |
The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Doxazosin; Female; Humans; Male; Middle Aged; Pain Measurement; Prazosin; Sulfonamides; Tamsulosin; Treatment Outcome; Ureteral Calculi | 2005 |
[Comparison of different drugs on the treatment of benign prostate hyperplasia].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Androstadienes; Double-Blind Method; Doxazosin; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Naphthalenes; Piperazines; Plant Extracts; Prazosin; Prostate; Prostatic Hyperplasia; Quality of Life; Secale; Sulfonamides; Tamsulosin; Treatment Outcome | 2007 |
[Efficacy of monotherapy with 15 antihypertensive agents in treating essential hypertension assessed by 24-hour ambulatory blood pressure monitoring].
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Doxazosin; Drug Therapy, Combination; Humans; Hypertension; Prazosin; Sulfonamides; Torsemide; Treatment Outcome | 2007 |
Comparison of 7 α(1)-adrenoceptor antagonists in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia:a short-term crossover study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Doxazosin; Humans; Indoles; Lower Urinary Tract Symptoms; Male; Middle Aged; Naphthalenes; Piperazines; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Treatment Outcome | 2013 |
58 other study(ies) available for doxazosin and terazosin
Article | Year |
---|---|
Structure-activity studies for a novel series of tricyclic substituted hexahydrobenz[e]isoindole alpha(1A) adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia (BPH).
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Cell Line; Dogs; Heterocyclic Compounds, 3-Ring; Indoles; Male; Pressure; Prostatic Hyperplasia; Radioligand Assay; Rats; Rats, Inbred SHR; Stereoisomerism; Structure-Activity Relationship; Urethra | 2000 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Cell Line; Dogs; Doxazosin; Drug Design; Humans; Indicators and Reagents; Indoles; Isoindoles; L Cells; Male; Mice; Models, Molecular; Molecular Conformation; Prazosin; Prostate; Prostatic Hyperplasia; Quinazolines; Radioligand Assay; Rats; Receptors, Adrenergic, alpha-1; Recombinant Proteins; Spleen; Structure-Activity Relationship; Vas Deferens | 2001 |
Range and sensitivity as descriptors of molecular property spaces in dynamic QSAR analyses.
Topics: Chemical Phenomena; Chemistry, Physical; Ligands; Models, Molecular; Molecular Conformation; Monte Carlo Method; Quantitative Structure-Activity Relationship; Receptors, Adrenergic, alpha-1; Solvents | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Computational approach to the basicity of a series of alpha1-adrenoceptor ligands in aqueous solution.
Topics: Chemical Phenomena; Chemistry, Physical; Computational Biology; Databases, Factual; Epinephrine; Guanidine; Hydrogen-Ion Concentration; Imidazoles; Kinetics; Ligands; Molecular Conformation; Norepinephrine; Receptors, Adrenergic, alpha-1; Solutions; Thermodynamics; Vasoconstrictor Agents; Water | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Naphthalenes; Piperazines; Rabbits; Receptors, Adrenergic, alpha-1; Structure-Activity Relationship | 2015 |
Effect of alpha 1 adrenoceptor antagonists on prostatic pressure and blood pressure in the anesthetized dog.
Topics: Adrenergic alpha-Antagonists; Affinity Labels; Anesthesia, Endotracheal; Animals; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Doxazosin; Male; Models, Biological; Phenylephrine; Piperazines; Prazosin; Pressure; Prostate; Quinazolines; Sulfonamides; Tamsulosin | 1994 |
A comparison of the effects of doxazosin and terazosin on the spontaneous sympathetic drive to the bladder and related organs in anaesthetized cats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Anesthesia; Animals; Blood Pressure; Cats; Doxazosin; Heart Rate; Male; Prazosin; Sympathetic Nervous System; Urinary Bladder | 1995 |
Alpha-adrenoceptor blocking drugs and female urinary incontinence: prevalence and reversibility.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Female; Humans; Prazosin; Prevalence; Urinary Incontinence | 1996 |
Effects of selective and nonselective alpha-1-adrenoceptor antagonists on intraurethral and arterial pressures in intact conscious dogs.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Pressure; Dogs; Doxazosin; Male; Prazosin; Prostatic Hyperplasia; Sulfonamides; Tamsulosin; Time Factors; Urethra | 1996 |
Alpha 1-adrenergic blockers: do they have a place in the prophylaxis of migraine?
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Child; Doxazosin; Female; Humans; Male; Middle Aged; Migraine Disorders; Prazosin | 1997 |
The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Blood Pressure; Doxazosin; Humans; Male; Prazosin; Prospective Studies; Prostatic Hyperplasia; Treatment Outcome; Urination | 1997 |
Alpha-adrenergic receptors regulate human lymphocyte amiloride-sensitive sodium channels.
Topics: 1-Methyl-3-isobutylxanthine; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Amiloride; Animals; Cell Transformation, Viral; Cells, Cultured; Cyclic AMP; Doxazosin; Endothelium, Vascular; Epithelial Sodium Channels; GTP-Binding Proteins; Herpesvirus 4, Human; Humans; Isoproterenol; Membrane Potentials; Norepinephrine; Patch-Clamp Techniques; Prazosin; Rats; Receptors, Adrenergic, alpha; Recombinant Proteins; Second Messenger Systems; Sodium Channels; Thionucleotides; Transcription, Genetic | 1998 |
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Apoptosis; Cell Division; Doxazosin; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Retrospective Studies | 1999 |
Doxazosin-to-terazosin switch for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Doxazosin; Drug Prescriptions; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; United States; United States Department of Veterans Affairs | 1999 |
Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Antagonists; Animals; Antineoplastic Agents; Apoptosis; Cell Division; Cells, Cultured; Doxazosin; Growth Inhibitors; Humans; Male; Mice; Mice, SCID; Muscle, Smooth; Neoplasm Transplantation; Prazosin; Prostate; Prostatic Neoplasms; Receptors, Adrenergic, alpha-1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides; Tamsulosin; Transplantation, Heterologous | 2000 |
Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Biopsy; Cell Division; Doxazosin; Humans; Male; Muscle, Smooth; Prazosin; Prostate; Prostatic Diseases; Prostatic Hyperplasia; Prostatic Neoplasms; Stromal Cells; Sulfonamides; Tamsulosin | 2000 |
Transurethral resection of the prostate: failure patterns and surgical outcomes in patients with symptoms refractory to alpha-antagonists.
Topics: Adrenergic alpha-Antagonists; Aged; Comorbidity; Doxazosin; Humans; Louisiana; Male; Postoperative Complications; Prazosin; Prostatic Hyperplasia; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Transurethral Resection of Prostate; Treatment Failure; Treatment Outcome; Urologic Diseases | 2000 |
A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster alpha1B-adrenoceptors.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Cell Line; Chromones; Cricetinae; Dose-Response Relationship, Drug; Doxazosin; Fibroblasts; Inositol Phosphates; Phenethylamines; Prazosin; Quinazolines; Rats; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Tetralones; Tritium | 2001 |
Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study.
Topics: Accidental Falls; Adrenergic alpha-Antagonists; Aged; Antihypertensive Agents; Cohort Studies; Comorbidity; Diabetes Mellitus; Diarrhea; Dizziness; Doxazosin; Drug Therapy, Combination; Fractures, Bone; Heart Diseases; Humans; Hypertension; Hypotension; Male; Neoplasms; Prazosin; Prostatic Hyperplasia; Retrospective Studies; Stroke; Syncope | 2001 |
Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Apoptosis; Dose-Response Relationship, Drug; Doxazosin; Humans; Male; Prazosin; Prostatic Neoplasms; Quinazolines; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Tumor Cells, Cultured | 2002 |
Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Retrospective Studies | 2002 |
Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of alpha1-adrenergic blockade.
Topics: 3T3 Cells; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Apoptosis; Calcineurin Inhibitors; Cell Survival; Cells, Cultured; Doxazosin; Heart; Humans; Mice; Myocardium; Piperazines; Prazosin; Rats; Rats, Sprague-Dawley | 2003 |
Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Anoikis; Cell Adhesion; Cell Survival; Doxazosin; Endothelial Growth Factors; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Neoplasm Invasiveness; Prazosin; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Tamsulosin; Transcription Factors; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
[Chiral separation and preparation of three new antagonists of alpha 1-adrenoceptors by chiral mobile phase HPLC].
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Chromatography, High Pressure Liquid; Doxazosin; Molecular Structure; Prazosin; Quinazolines | 2002 |
Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions.
Topics: Chromatography, High Pressure Liquid; Doxazosin; Prazosin; Reproducibility of Results; Stress, Mechanical | 2004 |
Herbal and vitamin supplement use in a prostate cancer screening population.
Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Adult; Aged; Colorado; Complementary Therapies; Dietary Supplements; Doxazosin; Drug Utilization; Family; Finasteride; Health Surveys; Humans; Male; Mass Screening; Middle Aged; Penile Erection; Phytotherapy; Plant Preparations; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Self Medication; Socioeconomic Factors; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Urination Disorders; Vitamins | 2004 |
A current review of medical therapy for benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Algorithms; Azasteroids; Cholestenone 5 alpha-Reductase; Doxazosin; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Urination Disorders | 2004 |
Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin.
Topics: Adrenergic alpha-Antagonists; Animals; Apoptosis; Cells, Cultured; Doxazosin; Electric Stimulation; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Patch-Clamp Techniques; Potassium Channels, Voltage-Gated; Prazosin; Xenopus | 2004 |
A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Doxazosin; Follow-Up Studies; Humans; Male; Middle Aged; Prazosin; Probability; Prostatic Hyperplasia; Quinazolines; Reference Values; Retrospective Studies; Risk Assessment; Severity of Illness Index; Sulfonamides; Tamsulosin; Treatment Outcome; Urination Disorders; Urodynamics | 2004 |
Alpha1-adrenergic antagonists and floppy iris syndrome: tip of the iceberg?
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Doxazosin; Humans; Intraoperative Complications; Iris Diseases; Phacoemulsification; Prazosin; Pupil; Quinazolines; Sulfonamides; Syndrome; Tamsulosin | 2005 |
In vivo studies on the effects of alpha1-adrenoceptor antagonists on pupil diameter and urethral tone in rabbits.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Dose-Response Relationship, Drug; Doxazosin; Male; Prazosin; Pupil; Quinazolines; Rabbits; Receptors, Adrenergic, alpha-1; Time Factors; Urethra | 2006 |
alpha-blocker treatment of urolithiasis.
Topics: Adrenergic alpha-Antagonists; Doxazosin; Drug Therapy, Combination; Glucocorticoids; Humans; Prazosin; Sulfonamides; Tamsulosin; Urolithiasis | 2006 |
The effects of systemic alpha-1 adrenergic antagonists on pupil diameter in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Doxazosin; Iris; Male; Prazosin; Pupil; Rats; Rats, Sprague-Dawley; Sulfonamides; Tamsulosin | 2007 |
Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antineoplastic Agents; Doxazosin; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Prazosin; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; United States | 2007 |
Human epididymal and prostatic tracts of vas deferens: different contraction response to noradrenaline stimulation in isolated organ bath assay.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-Agonists; Aged; Dose-Response Relationship, Drug; Doxazosin; Epididymis; Humans; In Vitro Techniques; Male; Middle Aged; Muscle Contraction; Muscle, Smooth; Norepinephrine; Organ Specificity; Prazosin; Prostate; Quinazolines; Stimulation, Chemical; Vas Deferens | 2007 |
alpha(1)-Adrenoceptor antagonists prevent paracetamol-induced hepatotoxicity in mice.
Topics: Acetaminophen; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Catecholamines; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Doxazosin; Erythrocytes; Gene Expression Regulation, Enzymologic; Glutamate-Cysteine Ligase; Glutathione; Heme Oxygenase-1; Liver; Liver Circulation; Liver Diseases; Male; Membrane Proteins; Mice; Prazosin; Protein Binding; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin; Time Factors; Transaminases | 2008 |
Intraoperative floppy-iris syndrome associated with systemic alpha blockers.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Cataract Extraction; Doxazosin; Humans; Intraoperative Complications; Iris Diseases; Male; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Syndrome; Tamsulosin | 2008 |
Effects of four different alpha(1)-adrenoceptor antagonists on alpha-adrenoceptor agonist-induced contractions in isolated mouse and hamster ureters.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Cricetinae; Doxazosin; Indoles; Male; Mesocricetus; Mice; Mice, Inbred ICR; Muscle Contraction; Norepinephrine; Prazosin; Quinazolines; Ureter | 2009 |
Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport.
Topics: Adrenergic alpha-Antagonists; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Daunorubicin; Digoxin; Doxazosin; Drug Resistance, Multiple; HeLa Cells; Humans; Neoplasm Proteins; Prazosin; Vinblastine | 2009 |
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Azasteroids; Capsules; Cholestenone 5 alpha-Reductase; Chromatography, High Pressure Liquid; Doxazosin; Drug Contamination; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Phytotherapy; Prazosin; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tablets; Tamsulosin | 2010 |
Comparison of effects of alpha receptor blockers on endothelial functions and coagulation parameters in patients with benign prostatic hyperplasia.
Topics: Adrenergic alpha-Antagonists; Aged; Blood Coagulation; Blood Pressure; Brachial Artery; Doxazosin; Endothelial Cells; Endothelium, Vascular; Humans; Male; Middle Aged; Prazosin; Prostate-Specific Antigen; Prostatic Hyperplasia; Quinazolines; Sulfonamides; Tamsulosin; Ultrasonography | 2011 |
Cell membrane chromatography competitive binding analysis for characterization of α1A adrenoreceptor binding interactions.
Topics: Adrenergic alpha-1 Receptor Antagonists; Binding, Competitive; Cell Line; Cell Membrane; Chromatography; Doxazosin; Humans; Methods; Phentolamine; Piperazines; Prazosin; Protein Binding; Quinazolines; Receptors, Adrenergic, alpha-1; Sulfonamides; Tamsulosin | 2011 |
Pharmacologic pupil dilation as a predictive test for the risk for intraoperative floppy-iris syndrome.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cohort Studies; Doxazosin; Drug Combinations; Humans; Intraoperative Complications; Iris Diseases; Male; Muscle, Smooth; Mydriatics; Phacoemulsification; Phenylephrine; Prazosin; Predictive Value of Tests; Prospective Studies; Pupil; Risk Factors; Sensitivity and Specificity; Sulfonamides; Syndrome; Tamsulosin; Tropicamide | 2011 |
Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding.
Topics: Adrenergic alpha-1 Receptor Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Thoracic; Dose-Response Relationship, Drug; Doxazosin; Imidazoles; In Vitro Techniques; Losartan; Male; Molecular Structure; Prazosin; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, alpha-1; Structure-Activity Relationship; Tetrazoles; Valine; Valsartan; Vasodilation; Vasodilator Agents | 2012 |
Prescriber monitoring for benign prostatic hyperplasia within a family medicine clinic: a comparison of medication classes.
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Doxazosin; Drug Therapy, Combination; Family Practice; Humans; Indoles; Male; Middle Aged; Practice Patterns, Physicians'; Prazosin; Prostatic Hyperplasia; Quinazolines; Retrospective Studies; Sulfonamides; Tamsulosin | 2012 |
Rapid and sensitive online determination of some selective α1-blockers by flow injection analysis with micelle-enhanced fluorescence detection.
Topics: Adrenergic alpha-1 Receptor Antagonists; Doxazosin; Flow Injection Analysis; Fluorescence; Internet; Micelles; Prazosin; Quinazolines; Spectrometry, Fluorescence; Time Factors | 2013 |
Rayleigh light scattering detection of three α1-adrenoceptor antagonists coupled with high performance liquid chromatograph.
Topics: Adrenergic alpha-Antagonists; Chromatography, High Pressure Liquid; Dimerization; Doxazosin; Dynamic Light Scattering; Humans; Hydrogen Bonding; Limit of Detection; Models, Molecular; Prazosin | 2015 |
Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Topics: Administrative Claims, Healthcare; Adrenergic alpha-Antagonists; Aged; Benzofurans; Doxazosin; Drug Therapy, Combination; Humans; Longitudinal Studies; Male; Mandelic Acids; Medication Adherence; Middle Aged; Muscarinic Antagonists; Ontario; Prazosin; Prostatic Hyperplasia; Prostatism; Pyrrolidines; Quinazolines; Retrospective Studies; Solifenacin Succinate; Sulfonamides; Tamsulosin; Tolterodine Tartrate | 2015 |
Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Apoptosis; Autophagy; Cell Death; Cell Line, Tumor; Cell Survival; Doxazosin; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Male; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prazosin; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfonamides; Tamsulosin | 2016 |
An efficient spectrofluorimetric method adopts doxazosin, terazosin and alfuzosin coupling with orthophthalaldehyde: Application in human plasma.
Topics: Doxazosin; Fluorescence; Humans; Limit of Detection; o-Phthalaldehyde; Plasma; Prazosin; Quinazolines; Spectrometry, Fluorescence | 2018 |
Micellar enhanced spectrofluorimetric approach for nanogram detection of certain α
Topics: Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Doxazosin; Fluorescence; Humans; Limit of Detection; Micelles; Pharmaceutical Preparations; Plasma; Prazosin; Quinazolines; Spectrometry, Fluorescence; Tablets | 2018 |
Evaluation of syncope association with α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Doxazosin; Humans; Hypertension; Indoles; Male; Middle Aged; Prazosin; Prostatic Hyperplasia; Quinazolines; Syncope; Tamsulosin | 2019 |
Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Cohort Studies; Databases, Factual; Denmark; Doxazosin; Female; Follow-Up Studies; Glycolysis; Humans; Male; Middle Aged; Parkinson Disease; Prazosin; Quinazolines; Registries; Risk Factors; Tamsulosin; United States | 2021 |